Danaher Names Julie Sawyer Montgomery CEO, Lifts 2026 EPS Outlook to $8.57–$8.62
DHR sits 48% above its 52-week low of $160.93.
Summary
Danaher installed Julie Sawyer Montgomery as president and CEO, with Rainer Blair retiring and staying on as an advisor through March 31, 2027. Alongside the transition, the company raised 2026 adjusted EPS guidance to $8.57–$8.62 and guided fourth-quarter core revenue growth of 4%–5%, with respiratory revenue a 150-basis-point drag and total core growth near 3%. The guidance bump follows the Q3 beat reported October 20, when adjusted EPS of $2.11 topped the $1.92 consensus on sales up 8.5% to $6.55B. Dan Loeb's firm also lifted its stake to 540,000 shares in Q2 2026 from 525,000 in Q1, worth about $102.8 million on June 30. The CEO handoff is the bigger item: Blair's exit was already flagged by his August stock sales, and Montgomery inherits a company carrying $26.5B of debt from the Masimo deal with core growth still running around 3%.
At the time of this announcement, DHR was trading at $237.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $163.4B. The 52-week trading range was $160.93 to $242.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.